FTC finalizes the Ascension and AmSurg consent order with seven surgery center divestitures and a prior notice duty
Sep 6, 2026 edition · GC-2026-0008 · Published 2026-09-06 · Version 2 · Final
Ascension must divest seven surgery centers and comply with a ten-year, geographically and service-limited prior-notice requirement. The August 24 order and August 25 announcement are distinct. Its thirty-day waiting periods and HSR exception matter for transaction planning; the order does not govern every future ASC acquisition.
What happened
The FTC announced on August 25 that it finalized a consent order addressing Ascension Health Alliance’s proposed $3.9 billion acquisition of AmSurg. The order requires seven ambulatory surgery center divestitures across Nashville, Panama City, Tulsa, Waco and Wichita. Six centers go to SC Affiliates and the Panama City center to Florida Gastroenterology Center. The FTC alleged harm to competition for specified gastroenterology, ophthalmology and orthopedic surgical services in those markets. The Commission’s vote was 2–0 after public comment. The final order itself was issued August 24; August 25 is the public announcement date, rather than the order’s issuance date.
Section X imposes a ten-year prior-notice duty for acquisitions of interests in ASCs performing the order-defined services in the order-defined areas. Notice must precede consummation by at least 30 days. A timely request for additional information triggers a further 30-day period after the response, subject to the order’s early-termination provision. The section excludes transactions for which the required Hart-Scott-Rodino notification has already been made. These limits are important: the obligation is neither a blanket notice rule for every ASC purchase nor a statement that every other health system has the same duty. The order also provides continuing compliance reports and restrictions on reacquiring the divested locations.
Scope and timing
- Authority status
- Final
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
A transaction remedy can create obligations extending well beyond asset divestiture. Deal teams need the actual service definitions, geographic scope, waiting periods and exceptions, rather than an abbreviated instruction to notify the FTC about every future acquisition.
Recommended action
Counsel should map this order’s specific notice, reporting and reacquisition restrictions to Ascension’s transaction processes. Other organizations should examine their own applicable orders and merger-review obligations; use this case’s market analysis as a case-specific reference rather than a universal FTC position.
Case details
- agencies
- Federal Trade Commission
- entities
- Ascension Health Alliance, AmSurg LLC
- action Type
- Consent order
- event Date
- 2026-08-24
- alleged Conduct
- Alleged competition harm in defined outpatient surgical services and five metropolitan areas from the proposed $3.9 billion acquisition.
- resolution
- Final order issued August 24, 2026 and announced August 25 following a 2–0 vote; seven ASC divestitures, ten-year scoped prior-notice requirements, defined waiting periods and HSR-notification exception, compliance reports and no-reacquisition restrictions.
Operational lessons
- Assign an owner to the actual notice and compliance-reporting obligations.
- Preserve the defined service/geographic scope and applicable HSR exception when screening transactions.
- Do not treat a case-specific market definition as a universal rule for another transaction.
Sources
- FTC Approves Final Consent Order in Ascension Health-AmSurg DealOfficial · Federal Trade Commission · 2026-08-25 · Source review 2026-09-06
- Ascension/AmSurg official final-order timeline, August 25, 2026Official · Federal Trade Commission · 2026-08-25 · Source review 2026-10-15
- Ascension/AmSurg Final Decision and Order, sections X–XVIOfficial · Federal Trade Commission · Source review 2026-10-15
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →